lutetium (177Lu) oxodotreotide

Lutetium (177Lu) oxodotreotide, marketed under the brand name Lutathera, is a radiopharmaceutical used in peptide receptor radionuclide therapy (PRRT). It consists of the beta-emitting radioisotope lutetium-177 chelated to dotatate (oxodotreotide), a somatostatin analog. The drug targets the somatostatin receptor subtype 2 (SSTR2), which is highly expressed on the surface of neuroendocrine tumor cells. Upon binding to SSTR2, the drug is internalized into the cell, where the emission of beta radiation from lutetium-177 causes localized DNA damage and subsequent cell death. It was developed by Advanced Accelerator Applications (AAA), a Novartis company, and is primarily indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The SEPTRALU study, sponsored by the Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM), is a significant retrospective observational study evaluating the efficacy and safety of this therapy in routine clinical practice within Spain.

Brand names

Lutathera

Other names

lutetium Lu 177 dotatateoxodotreotide177Lu-oxodotreotidelutetium (177Lu) dotatate